# G56W1 in Women With Postmenopausal Osteoporosis

> **NCT03720886** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Shenzhen Salubris Pharmaceuticals Co., Ltd.** · enrollment: 148 (estimated)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **BIOLOGICAL:** rhPTH（1-34） 28.2μg
- **BIOLOGICAL:** rhPTH（1-34） 56.5μg
- **BIOLOGICAL:** teriparatide acetate(Teribone™)

## Key facts

- **NCT ID:** NCT03720886
- **Lead sponsor:** Shenzhen Salubris Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-10-01
- **Primary completion:** 2020-05-31
- **Final completion:** 2020-08-31
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2018-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03720886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03720886, "G56W1 in Women With Postmenopausal Osteoporosis". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03720886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*